Mounjaro Subcutaneous Injections 2.5 mg from Japan for diabetes mellitus (terzipatide)
What are Mounjaro Subcutaneous Injection 2.5 mg for diabetes mellitus (terzipatide)?
Mounjaro Subcutaneous Injections featuring tirzepatide mark a significant breakthrough in addressing type 2 diabetes mellitus. Functioning as a dual agonist for the glucose-dependent insulinotropic polypeptide (GIP) / glucagon-like peptide-1 (GLP-1) receptors, tirzepatide employs a unique mechanism to enhance glucose control. Crafted for a once-weekly subcutaneous injection, this medication provides both extended effectiveness and increased convenience for patients.
The efficacy of Mounjaro Subcutaneous Injections lies in its capacity to boost glucose-dependent insulin secretion and enhance insulin activity. Through the activation of the GIP receptor, tirzepatide stimulates insulin secretion in response to elevated blood glucose levels, resulting in more efficient glucose utilization. Concurrently, its engagement with the GLP-1 receptor heightens insulin sensitivity in target tissues and suppresses glucagon secretion, contributing to enhanced glycemic control.
The weekly dosing regimen of Mounjaro Subcutaneous Injections not only simplifies the treatment plan but also fosters patient adherence. This sustained-release formulation ensures a lasting therapeutic impact, minimizing fluctuations in blood sugar levels throughout the week. In summary, Mounjaro Subcutaneous Injections with tirzepatide emerge as a promising therapeutic choice for those with type 2 diabetes, offering a blend of efficacy, convenience, and improved glucose management.
Active principles: terzipatide
Amount: standard kit
Maker: Mitsubishi Tanabe Pharma Corporation, Osaka, Japan
Indications: improving action of insulin and blood sugar level in patients with type II diabetes mellitus
How to take
For adults, start with a subcutaneous injection of 2.5 mg once a week. Following a 4-week duration, proceed to the maintenance dose of 5 mg administered subcutaneously once weekly. Your physician may make adjustments to the dosage based on your medical condition. If the desired effect is not achieved with a weekly injection of 5 mg, the dosage can be increased in increments of 2.5 mg, with intervals of at least 4 weeks or longer between adjustments. It is important to note that the maximum weekly dose should not exceed 15 mg.
Keep in mind that each injection of this medication contains 2.5 mg of the active ingredient. Administer the injection on the same day every week.
This medication is intended for subcutaneous injection, targeting the skin in the abdominal or thigh areas. If assisted by qualified medical personnel, injection into the upper arm is permissible. Ensure that each injection is administered to a slightly different spot within the chosen area of your body.
Contraindications: the following patients should not use this medicine:
- Pregnant, possibly pregnant or breastfeeding women,
- Patients with diabetic ketoacidosis, diabetic coma, precoma, type 1 diabetes,
- Patients with severe infections or surgery.
- Patients with gastrointestinal disorders like a gastroparesis, etc.,
- Patients with a history of pancreatitis,
- Patients with pituitary abnormality or adrenal disease,
- Patients who are unable to take enough meals, nutrition or are debilitating condition,
- Patients doing strenuous physical exercise or consuming large amounts of alcohol,
- Patients with proliferative diabetic retinopathy or diabetic macular edema or non-proliferative diabetic retinopathy requiring acute treatment or a history of those.
Patients must adhere diligently to their prescribed diet and exercise routines. While on this medication, regularly monitor both blood sugar and urine sugar levels. Be mindful of the potential for hypoglycemia (low blood sugar) and exercise caution during activities that pose risks, such as working at heights or driving. Inform your family and those in close proximity about the potential risk of hypoglycemia. If symptoms like intense hunger, cold sweats, or trembling limbs manifest, promptly consume sugar or sugar-rich foods.
In the event of any unusual symptoms—such as severe abdominal pain with vomiting, a palpable lump in the neck, significant weight loss, vision loss or a narrowing field of vision, continuous diarrhea, weakness, dizziness, or lightheadedness—seek immediate consultation with your doctor.
For pregnant women or those planning pregnancy, be mindful of potential fetal toxicity based on animal studies. Consult your doctor before using this medication.
Should an allergic reaction occur, discontinue the medication and promptly consult with your doctor. If you are taking any other medications, consult with your doctor before initiating use.